ANA
LLUCH HERNANDEZ
EMÉRITO/A UNIVERSIDAD
![Foto de ANA](/img/nophoto.png)
![Foto de Instituto de Investigación Sanitaria Fundación para la Investigación del Hospital Clínico de Valencia](/img/noimage_org.png)
Instituto de Investigación Sanitaria Fundación para la Investigación del Hospital Clínico de Valencia
Valencia, EspañaPublikationen in Zusammenarbeit mit Forschern von Instituto de Investigación Sanitaria Fundación para la Investigación del Hospital Clínico de Valencia (14)
2022
-
Targeting HER2-AXL heterodimerization to overcome resistance to HER2 blockade in breast cancer
Science Advances, Vol. 8, Núm. 20
2021
2020
-
Circulating mir-99a-5p expression in plasma: A potential biomarker for early diagnosis of breast cancer
International Journal of Molecular Sciences, Vol. 21, Núm. 19, pp. 1-14
2019
-
A Pathology-Based Combined Model to Identify PAM50 Non-luminal Intrinsic Disease in Hormone Receptor-Positive HER2-Negative Breast Cancer
Frontiers in Oncology, Vol. 9, Núm. APR
-
A two-gene epigenetic signature for the prediction of response to neoadjuvant chemotherapy in triple-negative breast cancer patients
Clinical Epigenetics, Vol. 11, Núm. 1
-
Dynamic clonal remodelling in breast cancer metastases is associated with subtype conversion
European Journal of Cancer, Vol. 120, pp. 54-64
-
The miRNA-449 family mediates doxorubicin resistance in triple-negative breast cancer by regulating cell cycle factors
Scientific Reports, Vol. 9, Núm. 1
2017
-
Defective cyclin B1 induction in trastuzumab-emtansine (T-DM1) acquired resistance in HER2-positive breast cancer
Clinical Cancer Research, Vol. 23, Núm. 22, pp. 7006-7019
2015
-
MicroRNA Profile in Response to Doxorubicin Treatment in Breast Cancer
Journal of Cellular Biochemistry, Vol. 116, Núm. 9, pp. 2061-2073
2014
-
Oxidative stress in susceptibility to breast cancer: Study in Spanish population
BMC Cancer, Vol. 14, Núm. 1
-
Retrospective analysis of the use of G-CSF and its impact on dose response for anthracycline plus taxane-based schedules in early breast cancer
Clinical and Translational Oncology, Vol. 16, Núm. 9, pp. 814-822
2010
-
¿Qué avances nos ofrece la moderna Oncología?
Anales (Reial Acadèmia de Medicina de la Comunitat Valenciana), Núm. 11
2005
-
Development of a questionnaire to measure health-related quality of life (HRQoL) in patients with bone metastases (BOMET-QoL)
Journal of Outcomes Research, Vol. 9, Núm. 15-27, pp. 15-27